It’s time to change how we treat anxiety
We are a biopharmaceutical company unlocking the potential for drug discovery in complex biological systems starting with a new class of anti-anxiety medication.
A multi-target approach that matches the complexities of the limbic system
A novel screening method that allows for rapid drug discovery
A library of safe, validated compounds with demonstrated therapeutic effects
Society has an anxiety problem
We need better medications, but new drug classes haven’t been developed in decades. We’re changing that.
Anxiety is on the rise
42% of Americans report anxiety problems. Economic uncertainty, social media, and the pandemic are all taking their toll on our mental health, especially among adolescents.
The available drugs aren’t enough
13% of Americans are medicated for anxiety, but current options are inadequate at best and harmful at worst. SSRIs have slow onset and unpredictable efficacy. Benzodiazepines can have devastating side effects.
It’s time to develop drugs differently
The prevailing single-target drug development paradigm has not been successful because it does not deal with the complex neuronal dysregulation underlying anxiety disorders. Cannex Scientific’s approach to drug discovery is changing this.
Cannex Scientific is shifting the drug discovery paradigm
A multi-target approach
The drugs we develop target multiple sites in the system underlying anxiety.
More about our approach →
Novel screening technologies
Brain organoids allow us to screen our compounds in an in vitro system that reflects the complexity of the neuronal system. Combined with a sophisticated in vivo test, we are able to rapidly identify drug clinical candidates.
More about our organoids →
Our chemical library consists of compounds that have demonstrated therapeutic benefits and safety.
More about our compounds →